 The results of pre-clinical in-vivo research studies suggested that Clearminds drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. TEL AVIV, Israel, Jan. 17, 2023 GLOBE NEWSWIRE SciSparc Ltd. Nasdaq: SPRC Company or SciSparc, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to... The post SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc... 